Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48361 | 1.00 | GPR35 (0.53) | GPR35TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL3206927 | 0.88 | GPR35 (0.55) | GPR35TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL48359 | 0.88 | GPR35 (0.55) | GPR35TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL11250446 | 0.87 | GPR35 (0.50) | GPR35TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL11250442 | 0.87 | GPR35 (0.50) | GPR35TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL17005575 | 0.85 | TSHR (0.51) | GPR35TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL1652615 | 0.85 | GPR35 (0.51) | GPR35TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL2373772 | 0.85 | GPR35 (0.51) | GPR35TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL57737 | 0.84 | ALDH1A1 (0.58) | ALDH1A1MEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL57738 | 0.84 | ALDH1A1 (0.58) | ALDH1A1MEN1KMT2ATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114094175-A | Secondary battery | 珠海冠宇电池股份有限公司 | 2022-02-25 | — | — | CN | claimed |
| US-8445734-B2 | Photolabile protective groups for improved processes to prepare oligonucleotide arrays | NIGU CHEMIE GMBH (DE) | 2013-05-21 | — | — | US | claimed |
| US-5446134-A | Reacting bis(fluorosulfonyl)methane salt with cyanogen halide or pseudohalide | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1995-08-29 | — | — | US | claimed |
| US-20250339552-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC (CA) | 2025-11-06 | — | — | US | disclosed |
| US-12433952-B2 | Antibody-drug conjugates targeting folate receptor alpha and methods of use | ZYMEWORKS BC INC. (CA) | 2025-10-07 | — | — | US | disclosed |
| US-20250295799-A1 | ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2025-09-25 | — | — | US | disclosed |
| US-20250281634-A1 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A DRUG MOIETY | TUBULIS GMBH (DE) | 2025-09-11 | — | — | US | disclosed |
| EP-4605426-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | Zymeworks BC Inc. (CA) | 2025-08-27 | — | — | EP | disclosed |
| US-20250235548-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2025-07-24 | — | — | US | disclosed |
| EP-4554984-A1 | MANNOSYLATED AMINE DEXTRAN DRUG DELIVERY VEHICLES WITH DEGRADABLE DISULFIDE/CARBONATE LINKERS TARGETING PAYLOADS TO CD206 EXPRESSING CELLS | Navidea Biopharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-119948062-A | NAPI 2B-targeted antibody-drug conjugates and methods of use thereof | 酵活英属哥伦比亚有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-6030941-A | FOR DELIVERY OF DRUGS AND OTHER COMPOUNDS ACROSS LIPID LAYERS | AVI BIOPHARMA, INC. (US) | 2000-02-29 | — | — | US | disclosed |
| EP-0966303-A2 | POLYPEPTIDE CONJUGATES FOR TRANSPORTING SUBSTANCES ACROSS CELL MEMBRANES | ANTIVIRALS INC. (US) | 1999-12-29 | — | — | EP | disclosed |
| EP-0932391-A2 | FUSOGENIC LIPOSOME COMPOSITION AND METHOD | SEQUUS PHARMACEUTICALS, INC. (US) | 1999-08-04 | — | — | EP | disclosed |
| WO-1998016202-A2 | FUSOGENIC LIPOSOME COMPOSITION AND METHOD | SEQUUS PHARMACEUTICALS, INC. (US) | 1998-04-23 | — | — | WO | disclosed |
| US-5733563-A | CROSSLINKED MIXTURE OF AQUEOUS SOLUTION OF POLYOXYETHYLENE GLYCOL ACTIVATED WITH 4-NITROPHENYL CHLOROFORMATE REACTIVE WITH PROTEIN ALBUMIN CONTAINING FREE ACID, HYDROXY, MERCAPTAN AND AMINE GROUPS; USED FOR CONTROLLED DRUG DELIVERY | UNIVERSITE DU QUEBEC A MONTREAL (CA) | 1998-03-31 | — | — | US | disclosed |
| WO-1997040854-A2 | POLYPEPTIDE CONJUGATES FOR TRANSPORTING SUBSTANCES ACROSS CELL MEMBRANES | ANTIVIRALS INC. (US) | 1997-11-06 | — | — | WO | disclosed |
| EP-0705298-A1 | ALBUMIN BASED HYDROGEL | UNIVERSITE DU QUEBEC A MONTREAL (CA) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995015352-A1 | ALBUMIN BASED HYDROGEL | UNIVERSITE DU QUEBEC A MONTREAL (CA) | 1995-06-08 | — | — | WO | disclosed |
| US-5221798-A | Changing the regiopurity of mixtures containing 4,4'-disubstituted diphenyl carbonates | AMOCO CORPORATION (US) | 1993-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339552-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | FOLR1, FOLR2, DHFR | GPR35 920/4885TSHR 71/4885ALDH1A1 305/4885 |
| US-20250281634-A1 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A DRUG MOIETY | CALCR, BCR, PTH1R | GPR35 487/4885TSHR 214/4885ALDH1A1 1805/4885 |
| US-12433952-B2 | Antibody-drug conjugates targeting folate receptor alpha and methods of use | FOLR1, FOLR2, DHFR | GPR35 920/4885TSHR 71/4885ALDH1A1 305/4885 |
| US-20250235548-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | SLC34A2, SLC20A2, SLC34A1 | GPR35 3294/4885TSHR 4009/4885ALDH1A1 509/4885 |
| US-20250295799-A1 | ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USE | B3GAT3, GALNT3, GOLGA3 | GPR35 713/4885TSHR 3032/4885ALDH1A1 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.